Selected Publications

Rapid and Robust CD4+ and CD8+ T-, NK-, B-Cell, Dendritic Cell, and Monocyte Reconstitution after Nicotinamide-Expanded Cord Blood Transplantation.
Boelens J.J. Presented at the 2019 Transplantation & Cellular Therapy (TCT) Meetings of American Society for Blood and Marrow Transplantation (ASBMT) and Center for International Blood and Marrow Transplant Research (CIBMTR).

First-in-Human Phase I Study of Nicotinamide-Expanded Related Donor Natural Killer Cells for the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma and Multiple Myeloma
Bachanova V. Presented at the 2019 TCT Meetings of ASBMT and CIBMTR.

Ex Vivo Nicotinamide-Expanded (NAM-Expanded) Unrelated Cord Blood (UCB) Transplantation for Refractory Severe Aplastic Anemia Results in Rapid Engraftment and Expedites Immune Recovery
Clara J. Presented at the 2019 TCT Meetings of ASBMT and CIBMTR.

Phase I/II Study of Stem-Cell Transplantation Using a Single Cord Blood Unit Expanded Ex Vivo with Nicotinamide
Horwitz M.E., Wease S., Blackwell B., et al. Journal of Clinical Oncology. 2018 DOI: 10.1200/JCO.18.00053.

Rapid and Robust CD4+ and CD8+ T-, NK-, B- and Monocyte Cell Reconstitution After Nicotinamide-Expanded Cord Blood Transplantation
De Koning C., Horwitz M.E., Sanz G. et al. Presented at the 2018 American Society for Hematology (ASH) Annual Meeting.

Phase I Study of Nicotinamide-Expanded Related Donor Natural Killer (NK) Cells for the Treatment of Relapsed/Refractory CD20+ non-Hodgkin Lymphoma
Bachanova V., McKenna, Jr., D.H., Luo X. et al. Presented at the 2018 International Meeting on Advances in Malignant Lymphoma.

Rapid and Robust CD4+ and CD8+ T-, NK-, B- and Monocyte Cell Reconstitution after Nicotinamide-Expanded Cord Blood Transplantation
Boelens J.J. Presented at 2018 International Society for Cellular Therapy Annual Meeting.

Enhanced In Vivo Persistence and Proliferation of NK Cells Expanded in Culture with the Small Molecule Nicotinamide: Development of a Clinical-applicable Method for NK Expansion
Peled T., Brachya G., Persi N. et al. Presented at the 2017 ASH Annual Meeting.

NiCord Single Unit Expanded Umbilical Cord Blood Transplantation (UCBT): Final Results of a Multicenter Phase I/ II Trial
Horwitz M. and Sanz G. Presented at the 2017 ASH Annual Meeting.

Transplantation of Ex Vivo Expanded Umbilical Cord Blood (NiCord) Decreases Early Infection and Hospitalization
Anand S., Thomas S., Hyslop T. et al. Biol Blood Marrow Transplant. 2017 Jul;23(7):1151-1157.

Successful Engraftment and Cure of Sickle Cell Disease after Co-transplantation of NiCord® (Ex Vivo Expanded UCB Progenitor Cells with Nicotinamide) and a Second Unmanipulated Cord Blood Unit after Myeloablative Chemotherapy in Children with Severe Sickle Cell Disease
Parkikh S.H., Brochstein J., Martin P.L. et al. Presented at the 2017 ASH Annual Meeting.

NiCord Single Unit Expanded Umbilical Cord Blood Transplantation: Results of Phase I/II Trials
Horwitz M., Montesinos P., Kurtzberg J. et al. Presented at the 2016 American Society of Clinical Oncology Annual Meeting.

Results of Nicord Phase I–II Trials and Plans for Phase III Trial
Horwitz M. Presented at the 2016 International Cord Blood Symposium.

Transplantation of Ex vivo Expanded Umbilical Cord Blood (NiCord®) Results in Decreased Infection Burden and Hospital Length of Stay in the First 100 Days
Anand S., Thomas S., Corbet K. et al. Presented at the 2016 European Society for Blood and Marrow Transplantation.

Nicord Expands Haematopoietic Stem Cells and Provides Prompt and Durable Engraftment in Patients Undergoing Cord Blood Transplantation for Haematological Malignancies and Sickle Cell Disease: Results of Early Phase Clinical Trials Using Fresh and Crypreserved Product
Kurtzberg J., Horwitz M., Sanz G.F. et al. Presented at the 2013 European School of Haematology Annual Meeting.